Comparative efficacy of bilastine, desloratadine and rupatadine in the suppression of wheal and flare response induced by intradermal histamine in healthy volunteers

References

• Thomsen SF. Epidemiology and natural history of atopic diseases. Eur Clin Respir J 2015;2:24642
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl 86):8-160
   PubMed Web of Science ®Google Scholar
• Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010;126:466-76
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014;69:868-87
   PubMed Web of Science ®Google Scholar
• del Cuvillo A, Mullol J, Bartra J, et al. Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol 2006;16(Suppl 1):3-12
   PubMedGoogle Scholar
• Kreutner W, Hey JA, Anthes J, et al. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung 2000;50:345-52
   PubMed Web of Science ®Google Scholar
• Wen J, Hong Z, Wu Y, et al. Simultaneous determination of rupatadine and its metabolite desloratadine in human plasma by a sensitive LC-MS/MS method: application to the pharmacokinetic study in healthy Chinese volunteers. J Pharm Biomed Anal 2009;49:347-53
   PubMed Web of Science ®Google Scholar
• Sun C, Li Q, Pan L, et al. Development of a highly sensitive LC-MS/MS method for simultaneous determination of rupatadine and its two active metabolites in human plasma: application to a clinical pharmacokinetic study. J Pharm Biomed Anal 2015;111:163-8
   PubMed Web of Science ®Google Scholar
• Anthes JC, Gilchrest H, Richard C, et al. Biochemical characterization of desloratadine, a potent antagonist of the human histamine H1 receptor. Eur J Pharmacol 2002;449:229-37
   PubMed Web of Science ®Google Scholar
• Merlos M, Giral M, Balsa D, et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). Pharmacol Exp Ther 1997;280:114-21
   PubMed Web of Science ®Google Scholar
• Izquierdo I, Merlos M, García-Rafanell J. Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today (Barc) 2003;39:451-68
   PubMed Web of Science ®Google Scholar
• Mullol J, Bousquet J, Bachert C, et al. Update on rupatadine in the management of allergic disorders. Allergy 2015;70(Suppl100):1-24
   Web of Science ®Google Scholar
• Picado C. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin Pharmacother 2006;7:1989-2001
   PubMed Web of Science ®Google Scholar
• Corcóstegui R, Labeaga L, Innerárity A, et al. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D 2005;6:371-84
   Google Scholar
• Scaglione F. Safety profile of bilastine: 2nd generation h1-antihistamines. Eur Rev Med Pharmacol Sci 2012;16:1999-2005
   PubMed Web of Science ®Google Scholar
• Tyl B, Kabbaj M, Azzam S, et al. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis. J Clin Pharmacol 2012;52:893-903
   PubMed Web of Science ®Google Scholar
• Church MK, Maurer M. H(1)-antihistamines and urticaria: how can we predict the best drug for our patient? Clin Exp Allergy 2012;42:1423-9
   PubMed Web of Science ®Google Scholar
• Monroe EW, Daly AF, Shalhoub RF. Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines. J Allergy Clin Immunol 1997;99:S798-S806
   Google Scholar
• Bachert C, Kuna P, Sanquer F, et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009;64:158-65
   PubMed Web of Science ®Google Scholar
• Lukat K, Rivas P, Roger A, et al. A direct comparison of efficacy between desloratadine and rupatadine in seasonal allergic rhinoconjunctivitis: a randomized, double-blind, placebo-controlled study. J Asthma Allergy 2013;6:31-9
   PubMedGoogle Scholar
• García-Gea C, Martínez-Colomer J, Antonijoan RM, et al. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psychopharmacol 2008;28:675-85
   PubMed Web of Science ®Google Scholar
• Church MK. Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans. Inflamm Res 2011;60:1107-12
   PubMed Web of Science ®Google Scholar
• Purohit A, Melac M, Pauli G, Frossard N. Comparative activity of cetirizine and desloratadine on histamine-induced wheal-and-flare responses during 24 hours. Ann Allergy Asthma Immunol 2004;92:635-40
   PubMed Web of Science ®Google Scholar
• Antonijoan R, García-Gea C, Puntes M, et al. Comparison of inhibition of cutaneous histamine reaction of ebastine fast-dissolving tablet (20 mg) versus desloratadine capsule (5 mg): a randomized, double-blind, double-dummy, placebo-controlled, three-period crossover study in healthy, nonatopic adults. Clin Ther 2007;29:814-22
   PubMed Web of Science ®Google Scholar
• Antonijoan RM, García-Gea C, Puntes M, et al. A comparison of ebastine 10 mg fast-dissolving tablet with oral desloratadine and placebo in inhibiting the cutaneous reaction to histamine in healthy adults. Clin Drug Investig 2007;27:453-61
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Gillman SA. Efficacy of fexofenadine versus desloratadine in suppressing histamine-induced wheal and flare. Allergy Asthma Proc 2007;28:67-73
   PubMed Web of Science ®Google Scholar
• Dhanya NB, Thasleem Z, Rai R, Srinivas CR. Comparative efficacy of levocetirizine, desloratadine and fexofenadine by histamine wheal suppression test. Indian J Dermatol Venereol Leprol 2008;74:361-3
   PubMed Web of Science ®Google Scholar
• Denham KJ, Boutsiouki P, Clough GF, Church MK. Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. Inflamm Res 2003;52:424-7
   PubMed Web of Science ®Google Scholar
• Popov TA, Dumitrascu D, Bachvarova A, et al. A comparison of levocetirizine and desloratadine in the histamine-induced wheal and flare response in human skin in vivo. Inflamm Res 2006;55:241-4
   PubMed Web of Science ®Google Scholar
• Frossard N, Strolin-Benedetti M, Purohit A, Pauli G. Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine. Br J Clin Pharmacol 2008;65:172-9
   PubMed Web of Science ®Google Scholar
• Bulca S, Bayramgürler D, Odyakmaz Demirsoy E, et al. Comparison of effects of 5 and 10 mg oral desloratadine and levocetirizine on histamine-induced wheal and flare response in healthy volunteers. J Dermatolog Treat 2013;24:473-6
   PubMed Web of Science ®Google Scholar
• Sádaba B, Azanza JR, Gomez-Guiu A, Rodil R. Critical appraisal of bilastine for the treatment of allergic rhinoconjunctivitis and urticaria. Ther Clin Risk Manag 2013;9:197-205
   PubMed Web of Science ®Google Scholar
• Barbanoj MJ, García-Gea C, Morte A, et al. Central and peripheral evaluation of rupatadine, a new antihistamine/platelet-activating factor antagonist, at different doses in healthy volunteers. Neuropsychobiology 2004;50:311-21
   PubMed Web of Science ®Google Scholar
• Church MK. Efficacy and tolerability of rupatadine at four times the recommended dose against histamine- and platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males. Br J Dermatol 2010;163:1330-2
   PubMed Web of Science ®Google Scholar
• Devillier P, Bousquet J. Inhibition of the histamine-induced weal and flare response: a valid surrogate measure for antihistamine clinical efficacy? Clin Exp Allergy 2007;37:400-14
   PubMed Web of Science ®Google Scholar
• Sánchez J, Zakzuk J, Cardona R. Prediction of the efficacy of antihistamines in chronic spontaneous urticaria based on initial suppression of the histamine- induced wheal. J Investig Allergol Clin Immunol 2016;26:177-184
   PubMed Web of Science ®Google Scholar